News headlines about Thermo Fisher Scientific (NYSE:TMO) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Thermo Fisher Scientific earned a news impact score of 0.16 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 46.7363488425652 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news headlines that may have impacted Accern’s analysis:

TMO has been the subject of several analyst reports. Argus reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. Cowen restated a “buy” rating and set a $200.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, September 1st. Morgan Stanley restated an “overweight” rating and set a $220.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, September 6th. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price target for the company in a research note on Thursday, September 7th. Finally, Barclays restated an “overweight” rating and set a $215.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus price target of $205.21.

Shares of Thermo Fisher Scientific (NYSE:TMO) traded up $1.30 during trading hours on Monday, reaching $193.57. The company’s stock had a trading volume of 1,305,526 shares, compared to its average volume of 1,573,631. The firm has a market capitalization of $77,099.31, a price-to-earnings ratio of 21.13, a PEG ratio of 1.76 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. Thermo Fisher Scientific has a 12 month low of $139.88 and a 12 month high of $201.20.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. During the same quarter last year, the firm earned $2.03 earnings per share. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. research analysts predict that Thermo Fisher Scientific will post 9.36 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.19%.

In other news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total value of $9,419,500.00. Following the completion of the sale, the chief executive officer now owns 252,577 shares in the company, valued at $47,582,981.03. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.49% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with's FREE daily email newsletter.